IL5 and chronic obstructive pulmonary disease: Biologics targeting IL-5 and its receptor α (IL-5Rα) may benefit patients with COPD; in selected eosinophilic COPD populations, these agents significantly reduce annual exacerbation rates and serious adverse events (142, 143).